Ichiro Abe. “Efficacy and Safety of Low-Dose Ipragliflozin, a Selective Sodium Glucose Transporter 2 Inhibitor, in Patients With Type 2 Diabetes Mellitus”. International Journal of Allied Medical Sciences and Clinical Research, vol. 4, no. 3, Aug. 2020, pp. 376-82, doi:10.61096/ijamscr.v4.iss3.2016.376-382.